In the fall of 2016, the FDA announced its intent to study the effective communication of prescription drug risk information in character-space-limited online formats (i.e., Google sponsored links, Twitter). As standard practice, the FDA invited commentary from the industry. Intouch Solutions partnered with pharmaceutical clients and the Kulkarni Law Firm (Kulkarni) to answer that call, submitting recommendations for optimizing the study design and stimuli.
Recently, the FDA announced it plans to adjust the original study design. Upon review, we were pleased to see these changes were directly influenced by our recommendations.
This POV details how the comments that Intouch and Kulkarni submitted directly affected the proposed research and changed the course of the study to produce more relevant results.
Download the POV to get the whole story.